2009
The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence
Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA. The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence. American Journal On Addictions 2009, 19: 53-58. PMID: 20132122, PMCID: PMC3107713, DOI: 10.1111/j.1521-0391.2009.00003.x.Peer-Reviewed Original ResearchConceptsOpioid-negative urinesBuprenorphine/naloxoneUrine toxicology testsWeeks of treatmentWorse treatment outcomesTreatment outcomesCocaine useTreatment retentionMean weekBuprenorphine/naloxone maintenanceGreater percentageToxicology testsUrine toxicology resultsOpioid dependenceToxicology resultsPatientsTargeted interventionsWeeksNaloxoneOutcomesTreatmentBaselineUrineAssociationPercentage
1999
Plasma concentrations of buprenorphine 24 to 72 hours after dosing
Chawarski MC, Schottenfeld RS, O’Connor P, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug And Alcohol Dependence 1999, 55: 157-163. PMID: 10402160, DOI: 10.1016/s0376-8716(98)00192-6.Peer-Reviewed Original ResearchConceptsDose scheduleWithdrawal symptomsPlasma concentrationsDaily buprenorphine doseHigh-dose scheduleThrice-weekly scheduleAdministration of buprenorphineOpiate-dependent subjectsHigher plasma concentrationsUse of heroinBuprenorphine doseDaily administrationOutpatient clinicPlasma levelsSublingual administrationAgonist effectsOpiate useHeroin useLow doseHigh doseBuprenorphine solutionMg/70High dosesConcentration 24Dependent subjects